key: cord-0744951-h3dtnh28
authors: García, Marina; Kokkinou, Efthymia; Carrasco García, Anna; Parrot, Tiphaine; Palma Medina, Laura M; Maleki, Kimia T; Christ, Wanda; Varnaitė, Renata; Filipovic, Iva; Ljunggren, Hans‐Gustaf; Björkström, Niklas K; Folkesson, Elin; Rooyackers, Olav; Eriksson, Lars I; Sönnerborg, Anders; Aleman, Soo; Strålin, Kristoffer; Gredmark‐Russ, Sara; Klingström, Jonas; Mjösberg, Jenny
title: Innate lymphoid cell composition associates with COVID‐19 disease severity
date: 2020-12-14
journal: Clin Transl Immunology
DOI: 10.1002/cti2.1224
sha: 2aab3d1922974b66a265a539e9e26fcfe529dc2c
doc_id: 744951
cord_uid: h3dtnh28

OBJECTIVES: The role of innate lymphoid cells (ILCs) in coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is unknown. Understanding the immune response in COVID‐19 could contribute to unravel the pathogenesis and identification of treatment targets. Here, we describe the phenotypic landscape of circulating ILCs in COVID‐19 patients and identified ILC phenotypes correlated to serum biomarkers, clinical markers and laboratory parameters relevant in COVID‐19. METHODS: Blood samples collected from moderately (n = 11) and severely ill (n = 12) COVID‐19 patients, as well as healthy control donors (n = 16), were analysed with 18‐parameter flow cytometry. Using supervised and unsupervised approaches, we examined the ILC activation status and homing profile. Clinical and laboratory parameters were obtained from all COVID‐19 patients, and serum biomarkers were analysed with multiplex immunoassays. RESULTS: Innate lymphoid cells were largely depleted from the circulation of COVID‐19 patients compared with healthy controls. Remaining circulating ILCs revealed decreased frequencies of ILC2 in severe COVID‐19, with a concomitant decrease of ILC precursors (ILCp) in all patients, compared with controls. ILC2 and ILCp showed an activated phenotype with increased CD69 expression, whereas expression levels of the chemokine receptors CXCR3 and CCR4 were significantly altered in ILC2 and ILCp, and ILC1, respectively. The activated ILC profile of COVID‐19 patients was associated with soluble inflammatory markers, while frequencies of ILC subsets were correlated with laboratory parameters that reflect the disease severity. CONCLUSION: This study provides insights into the potential role of ILCs in immune responses against SARS‐CoV‐2, particularly linked to the severity of COVID‐19.

describe the phenotypic landscape of circulating ILCs in COVID-19 patients and identified ILC phenotypes correlated to serum biomarkers, clinical markers and laboratory parameters relevant in COVID-19. Methods. Blood samples collected from moderately (n = 11) and severely ill (n = 12) COVID-19 patients, as well as healthy control donors (n = 16), were analysed with 18-parameter flow cytometry. Using supervised and unsupervised approaches, we examined the ILC activation status and homing profile. Clinical and laboratory parameters were obtained from all COVID-19 patients, and serum biomarkers were analysed with multiplex immunoassays. Results. Innate lymphoid cells were largely depleted from the circulation of COVID-19 patients compared with healthy controls. Remaining circulating ILCs revealed decreased frequencies of ILC2 in severe COVID-19, with a concomitant decrease of ILC precursors (ILCp) in all patients, compared with controls. ILC2 and ILCp showed an activated phenotype with increased CD69 expression, whereas expression levels of the chemokine receptors CXCR3 and CCR4 were significantly altered in ILC2 and ILCp, and ILC1, respectively. The activated ILC profile of COVID-19 patients was associated with soluble inflammatory

Coronavirus disease 2019 , caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is of global concern, and major efforts to identify effective treatments and vaccines are currently underway. 1-4 SARS-CoV-2 affects mainly the respiratory tract, and infected individuals often manifest flu-like symptoms. While some patients recover within weeks, others progress to a severe stage of disease, typically including severe respiratory distress and hypoxia with later multi-organ failure, occasionally leading to death. 5, 6 Notably, a gradual progression to more severe disease stages coincides with the development of a hyperactivated immune response, triggering a systemic cytokine storm circulatory impairment, sometimes leading to circulatory shock. [7] [8] [9] Thus, there are reasons to believe that immunopathology involving the innate immune system plays a potent role behind severe morbidity and mortality in the critically ill COVID-19 patients. Currently, little information is available on the role of innate immune cells in COVID-19. Therefore, here we studied the role of innate lymphoid cell (ILC) in hospitalised COVID-19 patients.

Innate lymphoid cells are innate lymphocytes which, unlike T and B cells, lack rearranged antigen-specific receptors and cell surface markers associated with other lymphoid and myeloid lineages. 10 ILCs are categorised into five major groups: natural killer (NK) cells, ILC1, ILC2, ILC3 and lymphoid tissue inducer (LTi) cells. 10 Based on their transcription factor dependence and functional characteristics, ILC1, 11, [12] [13] [14] [15] and ILC3 16 are considered the innate counterparts of the specialised subsets of CD4 + T cells, that is Th1, Th2 and Th17 cells, respectively, while NK cells mirror the cytotoxic functions of CD8 + T cells. 10 Although ILCs exert their function primarily in tissues, distinct subsets of ILCs are found circulating in blood. 17, 18 The major blood ILC population is the ILC precursor (ILCp), with the capacity to home to peripheral tissues and differentiate to mature ILC subsets. 18 However, human blood also harbours the committed ILC lineages ILC1 and ILC2. ILC2 in blood express CRTH2 and CD161 and are dependent on the GATA binding protein-3 (GATA-3) transcription factor. 19 IFN-γ-producing ILCs, reminiscent of ILC1, have been identified in peripheral blood. 20 While their characterisation has been challenging because of the lack of unique surface markers, 21 studies have shown that blood ILC1 that produce IFN-γ express the chemokine receptor CXCR3. 20 Hence, CXCR3 serves as a marker to define the ILC1 subset in peripheral blood.

While little is known regarding ILCs in the context of human respiratory viral infections, studies performed in mice highlight their contribution during acute viral infection. More specifically, ILC2 have been suggested to accumulate in the lung of influenza virus-infected mice and promote lung homeostasis and tissue repair. 22 In contrast, ILC2, in concordance with T cells, were reported to contribute to allergic airway inflammation induced by influenza virus in mice. 23 In humans, ILCs have been investigated in acutely HIV-1-infected individuals where they were found to be depleted from the circulation. 24 To the best of our knowledge, ILCs have not yet been investigated in a human respiratory viral disease.

Understanding the immunopathogenesis of COVID-19 is urgently needed in order to help tackle the current pandemic. In the present study, we report a profound reduction in number of ILCs within the systemic circulation of COVID-19 patients. The remaining ILCs show dysregulated expression of markers associated with activation and migration. Furthermore, ILC frequencies are correlated to clinical parameters related to COVID-19 disease severity.

A total of 23 patients with either moderate (n = 11) or severe (n = 12) COVID-19 and 16 control donors were included in the study (Figure 1a ). The COVID-19 patients showed profound perturbations in inflammatory markers, coagulation factors, organ/muscle damage markers and biochemical, haematological and serological parameters (Supplementary figure 1) . A detailed summary of the patients' clinical and laboratory parameters is presented in Tables 1 and 2. A timeline summarising the major clinical events of the patients is shown in Figure 1b .

For the identification and analysis of peripheral blood ILCs, we used 18-parameter flow cytometry and a modification of a well-established gating strategy 25 (Supplementary figure 2a) . We found that the relative frequencies and absolute counts of total CD127 + ILCs (hereafter referred to as total ILCs), as well as the absolute counts of the specific subsets ILC1, ILC2 and ILCp, were decreased in peripheral blood of moderate and severe COVID-19 patients, while ILC2 counts were only reduced in severe, and not moderate, COVID-19 as compared with controls (Figure 2a-d) . Further characterisation of the remaining circulating ILC compartment showed reduced ILCp frequencies in COVID-19 patients, while the frequencies of ILC1 remained unchanged (Figure 2c and e). Of note, the moderately ill group showed elevated frequencies of both total ILC2 (Figure 2e) and CD117 − ILC2, as compared with the control group ( Figure 2f ).

Taken together, we observed a general ILC depletion as well as compositional changes in the circulating ILC compartment of COVID-19 patients. Interestingly, changes in the relative frequency of ILCs differed between the moderate and severe groups, prompting a more detailed phenotypical study of the ILCs.

To deepen our understanding of the differentiation, activation and migration of ILCs during COVID-19, we assessed differentiation (CD56 and NKp44) (Supplementary figure 3a) and activation (CD69, HLA-DR and Ki-67) markers as well as chemokine receptors (CCR4, CCR6 and CXCR3) and molecules associated with naivety and homing to lymphoid tissues (CD45RA and CD62L) on ILCs (Figure 3a-h) . Manual gating and unbiased principal component analysis (PCA) were used to simultaneously take into account the relative frequency of all the markers measured on ILCs.

This approach revealed a higher relative frequency of CD69-expressing total ILCs in patients as compared with controls ( Figure 3a) . Additionally, Ki-67, a marker of cell proliferation, was increased in severe compared with moderate COVID-19 but decreased in moderate COVID-19 compared with controls ( Figure 3a) . However, the overall Ki-67 expression level was low in all ILCs regardless of the study group, suggesting either a low proliferating capacity of ILCs in peripheral blood or migration of proliferative ILCs to tissues at an earlier stage. In line with an increase in CD69 in COVID-19 patients, we detected reduced frequencies of total ILCs expressing CD45RA and CD62L, two markers associated with ILC naivety, 18 in severe COVID-19 patients ( Figure 3a ). Additionally, we observed alterations in chemokine receptor expression between controls and moderate COVID-19 patients, revealing a reduction in the percentage of CXCR3 + and an increase in CCR4 + ILCs. The latter likely reflects the increase in ILC2 frequencies in these patients (Figure 2e ), as CCR4 is particularly highly expressed on ILC2 (Figure 3e ). Despite these changes in ILC phenotypes, the PCA could not discriminate between COVID-19 patients and controls on the basis of the total ILC data (Figure 3b ), suggesting that the COVID-19-related changes in total ILCs are ILC subset specific.

Indeed, we observed no changes in expression of markers associated with differentiation and activation in ILC1. There was, however, a slightly increased percentage of CCR4 + ILC1 cells in COVID-19 patients compared to controls (Figure 3c ). We also detected a reduction of CD56 + ILC1 in COVID-19 patients (Supplementary figure 3a). PCA illustrated these differences well, showing segregation of the ILC1 data on the basis of CCR4 for COVID-19 patients and CD56 for controls ( Figure 3d ).

In contrast, ILC2 displayed an activated phenotype in COVID-19 patients, showing higher frequencies of CD69 + and a tendency towards reduced frequencies of CD62L + cells, as compared with controls ( Figure 3e ). Interestingly, Ki-67, generally expressed at very low levels, was decreased in relative frequency in ILC2 from severe COVID-19 patients compared to the control group, possibly reflecting tissue recruitment of such cells in severe COVID-19. Indeed, we identified dysregulated chemokine receptor expression on ILC2 in COVID-19 patients, specifically CXCR3 and CCR6 which was significantly reduced in the patients as compared with controls ( Figure 3e , Supplementary figure 3b). PCA provided an illustration of these findings by segregating the ILC2 data from patients and controls based on CD69 expression for patients and chemokine receptors as well as CD62L and CD45RA for the controls (Figure 3f ). The latter two were, however, not statistically different between the groups (Figure 3e ).

ILCp showed an activated profile in COVID-19 patients, with increased CD69 and HLA-DR expression as compared with controls. Additionally, CXCR3 was decreased on ILCp in COVID-19 patients as compared with controls ( Figure 3g ). Although PCA did not separate the ILCp phenotype from patients and controls clearly, there was a tendency towards separation of ILCp from controls on the basis of CD62L and CD45RA ( Figure 3h ). These two markers showed reduced tendency but were not statistically significant in the manual gating ( Figure 3g ). Interleukin-6, ng L −1 < 7 6 2 ( 2 -150), n = 2 n/a 472.5 (33-8093) 0.0035 P-value: Mann-Whitney U-test, n/a: not available.

The bold values indicate statistical significance according to the following: *P < 0.05, **P < 0.01, ***P < 0.001.

Overall, these findings suggest that the ILCs remaining in the circulation of COVID-19 patients are activated and show an altered expression of chemokine receptors, particularly a decrease in CXCR3, possibly reflecting alterations in CXCR3ligand-dependent ILC recruitment to tissues. Bar plot summaries of the percentage of CD117 + and CD117 − ILC2 of total ILCs in control donors (n = 16), moderate (n = 11) and severe (n = 9) COVID-19 patients. (b, d, e, f) Statistical differences were tested using the Kruskal-Wallis test followed by Dunn's multiple comparisons test. Numbers in flow cytometry plots indicate percentage of cells within the mother gate. Bar graphs are shown as median AE IQR, *P < 0.05, **P < 0.01, ***P < 0.001. Patients with low cell numbers (fewer than 20 events) in the corresponding gate were removed from the analysis. (a, c, e, g) Statistical differences were tested using the Kruskal-Wallis test followed by Dunn's multiple comparisons. Bar graphs are shown as median AE IQR, *P < 0.05, **P < 0.01, ***P < 0.001. Patients with low cell numbers (fewer than 20 events) in the corresponding gate were removed from the analysis. In PCA plots, each dot represents one donor. Deceased patients in the severe group are indicated by a black dot. (3, 4, 1, 7, 11, 9, 5) out of total ILCs, in control donors (n = 9), moderate (n = 9), and severe (n = 9) COVID-19 patients. (g-i) Patients with fewer than 10 events per ILC subset (defined by the Phenograph-identified clusters) were excluded from analysis. Statistical differences were tested using the Kruskal-Wallis test followed by Dunn's multiple comparisons test. Bar graphs are shown as median AE IQR, *P < 0.05, **P < 0.01.

(UMAP) analysis confirmed and extended the findings obtained by manual gating in an unsupervised manner. As expected from manual gating, clear differences in ILC composition between controls and COVID-19 patients were observed when overlaying each group to the UMAP containing all concatenated ILC events (Figure 4a, Supplementary figure 2b) . Phenograph clustering yielded a total of 14 distinct clusters across patients and controls (Figure 4b ). Based on the relative expression of CRTH2, CD117 and CXCR3, clusters were identified as ILC1, ILC2 or ILCp (Figure 4c and d) . Thereafter, manually defined ILC subset gates that were overlaid into the UMAP (Figure 4e) showed a similar spatial distribution as the Phenograph-defined clusters belonging to each ILC subset, confirming the precision of the manual gating relative to the unsupervised analysis (Figure 4b) .

Next, we assessed each Phenograph-defined cluster. Validating the manual gating, CCR4 + ILC1 (cluster 14) was uniquely present in COVID-19 patients, while two additional CCR4 −/lo ILC1 clusters (2 and 6) were overrepresented in severe COVID-19 patients (Figure 4f and g) . For ILC2, cluster 8, containing CCR4 hi ILC2, was only present in COVID-19 patients and other two CCR6 + ILC2 clusters (10, 12) were accumulated in moderate patients (Figure 4f and h) . Corroborating again the findings from manual gating (Figure 3) , cluster 3, uniquely present in COVID-19 patients, corresponded to activated (CD69 + ) ILCp lacking CXCR3 (Figure 4f and i) . Furthermore, three ILCp clusters (1, 5 and 7) with an immature phenotype (CD45RA +/hi /CD62L +/hi ) were reduced in COVID-19 patients as compared with controls (Figure 4f and i), in support of the data obtained by manual gating (Figure 3) .

Altogether, the unsupervised analysis revealed clusters specifically accumulated in COVID-19 patients compared to controls and the presence of specific ILC phenotypes that associated to the disease severity. Importantly, several of the findings agreed with those obtained by manual gating. Specifically, we confirmed an increase in the relative frequency of CD69 + ILCp and a decrease in CXCR3 + ILCp in both moderate and severe COVID-19, an increase in ILC2 percentage specifically in moderate COVID-19 and an increased CCR4 expression among ILC1 in the patients. Figure 5 . Activation status and homing profile of peripheral blood ILCs associate with inflammation markers in COVID-19 patients. Spearman correlations between (a) serum IL-6 levels (pg mL −1 ) and the percentage of CD69 + ILCs and CD69 + ILCp; (b) serum IL-10 relative levels (NPX) and the percentage of CD69 + ILCs; (c) serum CXCL10 levels (pg mL −1 ) and the percentage of CD69 + ILCs and CD69 + ILCp; (d) serum CXCL10 and CXCL11 levels (pg mL −1 ) and the percentage of CXCR3 + ILCs; (e) serum CCL20 levels (pg mL −1 ) and the percentage of ILC2 and CCR4 + ILCs in COVID-19 patients. IL-6, CXCL10, CXCL11 and CCL20 serum absolute levels were measured with Magnetic Luminex Screening assay, and IL-10 relative levels with a proximity extension assay, where data are shown as normalised protein expression (NPX). Blue circles: moderate COVID-19 patients (n = 11); pink circles: severe COVID-19 patients (n = 11); black circles: deceased severe COVID-19 patients (n = 4). P < 0.05 was considered statistically significant. r s : Spearman's rank correlation coefficient. To analyse for potential factors involved in the activation and potential recruitment of ILCs to tissues in the COVID-19 patients, we examined correlations between ILCs and a wide array of soluble serum factors (Supplementary figure 4a and  b) . Based on our findings on altered frequencies of CXCR3 + and CD69 + ILCs in COVID-19 (Figure 3a) , we focused on selected chemokines (CCL20, CXCL10 and CXCL11) and factors previously reported to be increased in COVID-19 or other viral respiratory disease: IL-6, IL-10, IL18R1 and PD-L1. [7] [8] [9] [26] [27] [28] [29] [30] [31] Interestingly, we found that the percentage of activated (CD69 + ) total ILCs and activated ILCp positively correlated with serum IL-6 levels in the COVID-19 patients (Figure 5a) . Additionally, the relative levels of the cytokine IL-10 also positively correlated with the levels of CD69 + ILCs in the COVID-19 patients (Figure 5b) . Moreover, the percentage of CD69 + total ILCs and ILCp positively correlated with CXCL10 levels in the COVID-19 patients (Figure 5c ), suggesting that this chemokine is related to the increase in the percentage of activated ILCs that remain in the circulation of COVID-19 patients.

Furthermore, indicative of dysregulated ILC tissue migration in COVID-19, we observed a negative correlation of CXCL10 and CXCL11 levels (CXCR3 ligands), with the percentage of CXCR3 + ILCs in COVID-19 patients (Figure 5d ). Additionally, the percentage of CCR4 + total ILCs and ILC2 negatively correlated with CCL20 (ligand for CCR6) levels ( Figure 5e ). The latter correlation is in line with the high expression of CCR6 on circulating ILC2. 17 Of further interest, IL18R1 and PD-L1, involved in type 1 inflammation, 29, 32 negatively correlated with the level of CD45RA + ILCp, suggesting that the inflammatory status of COVID-19 patients may promote maturation, depletion and/or tissue migration of ILCp in the systemic circulation (Supplementary figure 4c) .

We next sought to integrate our flow cytometric data with the clinical and laboratory findings from the same patients. Clinical information and laboratory measurements (summarised in Tables 1 and 2) integrated in a PCA clustered the patients on the basis of disease severity (Figure 6a) with several haematological and biochemical factors particularly driving this separation (Figure 6b) .

We searched for potentially relevant correlations between ILCs and the clinical and laboratory parameters (Supplementary figure 5) .

The frequencies of ILC1 and ILC2 correlated with several of the measured parameters, whereas no correlations were found for ILCp frequencies (Supplementary figure 5) . The percentage of ILC1 positively correlated with LDH and serum SARS-CoV-2 IgG levels, which were significantly increased in severe COVID-19 patients (Figure 6c,  Supplementary figure 1) . ILC1 frequencies also positively correlated with parameters that did not differ between the two COVID-19 patient groups, i.e. platelet counts and days post-symptom debut (Figure 6c, Table 1 and 2) . The percentage of ILC2, in contrast, was negatively correlated with the leukocyte, neutrophil and platelet count (Figure 6d) . Interestingly, high neutrophil levels, which have been described as partial predictors of disease severity, 33 also contributed heavily to the separation between patient groups in the current study (Figure 6a and b) . Of note, neutrophils have been found to inhibit ILC2 function, thus preventing allergic airway inflammation. 34 Additionally, the relative frequency of ILC2 correlated negatively with levels of D-dimer, a coagulation factor that has been suggested as a systemic biomarker of disease severity in COVID-19 ( Figure 6d ). 33, 35 Finally, we observed a negative correlation between ILC2 frequencies and organ/muscle damage markers (myoglobin, troponin T, LDH) and the number of days since symptom debut (Figure 6d ). These findings suggest that among COVID-19 patients, elevated frequencies of ILC1 and decreased frequencies of ILC2 are hallmarks of COVID-19 patients with a clinical profile associated with severe disease.

We report unphysiologically reduced levels of ILCs in the circulation of COVID-19 patients, both in percentage and absolute counts, in line with a recent report, 36 and the overall reduction of peripheral blood lymphocytes described in COVID-19. 6, 27, 37, 38 In addition to the overall ILC depletion, we found major changes in the residual circulating ILC compartment in COVID-19 patients, including altered frequencies of ILC subsets, increased activation and dysregulated migration receptor expression. Our data imply that the circulating ILCs are activated and have differentiated and/or are differentially recruited to tissues, where they may contribute to the anti-viral defence.

Noteworthy, we found decreased circulating ILC2 frequencies in severe but not moderate COVID-19 patients, suggesting that ILC2 may be differentially regulated dependent on severity of disease. Supporting this, the relative frequency of ILC2 in COVID-19 patients correlated negatively with the coagulation factor D-dimer, previously shown to be associated with the development of severe disease 33, 35 as well as organ/muscle damage markers, suggesting that low ILC2 levels in COVID-19 patients could be indicative of a more severe disease outcome. Indeed, ILC2 have been shown to have a prominent role in lung tissue repair during influenza A infection in mice. 22 This was achieved through production of the epidermal growth factorrelated protein amphiregulin, also shown to be involved in promotion of regulatory T cells and cell survival in hepatitis C virus infection. 39, 40 The role for ILC2-derived amphiregulin in lung tissue repair in humans is unknown and deserves further exploration in COVID-19.

In contrast to ILC2, ILCp frequencies were diminished in all COVID-19 patients as compared with controls, suggesting their migration to the site of infection or differentiation into mature ILC subsets in the circulation. This has previously been described in an adoptive transfer mouse model. 18 In support of this hypothesis, both ILC2 and ILCp showed an activated phenotype, based on increased frequencies of CD69 + and/or HLA-DR + cells. This is in line with the recent discovery of increased frequencies of CD69 + NK cells in COVID-19. 41 Interestingly, in addition to its known role as an early activation marker, CD69 is also a marker of tissue residency. 42 Thus, the presence of the CD69expressing ILCs in circulation could also indicate retrograde migration from tissue to circulation after local tissue activation, as recently shown for resident memory T cells. 43 Furthermore, we observed that the CD69-expressing cells in the circulation of COVID-19 patients positively correlated with the levels of IL-6 and IL-10, suggesting that the inflammatory status in these patients could be the driver of ILC activation and/or recirculation. Additionally, these CD69expressing cells positively correlated with the chemokine CXCL10 in patients. In contrast, CXCR3 + ILCs negatively correlated with CXCR3 ligands CXCL10 and CXCL11, potentially indicating a CXCR3dependent tissue migration of ILCs in COVID-19. CXCR3 + ILCs include IFN-γ producing ILC1, 11, 20 which are accumulated in acute and chronic intestinal inflammation in humans. 11 While ILC1 are essential for clearance of cytomegalovirus in mice, 44 the role for ILC1 in human anti-viral immunity, including COVID-19, remains obscure and requires further exploration. Additionally, as ILC1 were defined as CD161 + cells in our study, future examination of CD127 + CD161 − CD117 − ILC-like cells in COVID-19 is warranted.

Lastly, the phenotypic characterisation of circulating ILCs performed in this study would benefit from additional analyses delineating the functionality of ILCs as well as the impact of the tissue microenvironment to their phenotype and function. Of special interest would be the study of ILCs from tissue resident sites, such as lung and intestine, which have been described as main sites of SARS-CoV-2 infection and shedding. [45] [46] [47] [48] We have previously reported increased ILC2 frequencies in the intestine of patients with inflammatory bowel disease 17 and in the lungs of patients with asthma, 49 likely due to their influx from the circulation. In line with this, it is possible that the lower ILC frequencies observed in severe as compared with moderate COVID-19 patients could indicate potential trafficking of ILC2 to inflamed infection sites as previously described in asthma 49 and cystic fibrosis. 50 In striking resemblance with the latter study, we observed the lowest frequencies of ILC2 in patients with the highest serum levels of CCL20, and reduced frequencies of CCR6 + ILC2 in COVID-19 patients. Hence, our data point towards a role for CCL20mediated recruitment of CCR6 + ILC2 to the lung of COVID-19 patients, where they could contribute to fibrosis. 50 To exhaust this and other possible roles for ILC2 in COVID-19, further studies at the tissue level are required.

In summary, this study provides a phenotypic characterisation of circulating ILCs of COVID-19 patients. We identified that altered frequencies of ILCs correlate with clinical and laboratory parameters linked to COVID-19 disease severity. Lastly, to the best of our knowledge, this is the first comprehensive study of ILCs in the context of a human respiratory viral infection. Thus, these data pave the way for a better understanding of the role of this innate immune cell compartment in other viral infectious diseases.

As a part of the Karolinska KI/K COVID-19 Immune Atlas, 23 COVID-19 patients (6 females and 17 males; median age 57 years; age range 18-74 years) positive for SARS-CoV-2 RNA by diagnostic RT-qPCR and hospitalised at the Karolinska University Hospital (Stockholm, Sweden) were included in the present study. Patients were classified as COVID-19 moderate (n = 11) and severe (n = 12), based on the peak supplementary oxygen received during hospitalisation until the time of inclusion in the study. The moderate group required low or no supplementary oxygen (low oxygen flow, ≤ 15 L min −1 ), out of whom 8 were hospitalised in the regular ward and 3 in the intensive care unit (ICU). These patients had median ordinal scale of 5 (IQR 4-5) at sampling. The severe group consisted of patients that were hospitalised in the ICU and required mechanical ventilation or extracorporeal membrane oxygenation (ECMO; one patient) provided within an intensive care setting. These patients had a median ordinal scale score of 7 (IQR 7-7) at sampling. This classification was in line with the 8-category ordinal scale described by Beigel et al. as well as in the WHO guidelines. 51, 52 Peripheral blood sample from all COVID-19 patients was collected 5-24 days (median 14 days; IQR 5-24 days) after symptom debut and 0-8 days after hospitalisation.

Sixteen donors (6 females and 10 males; median age 54 years; age range between 34 and 69 years), all SARS-CoV-2 IgG seronegative and symptom-free at the day of sampling, were included as a control group for this study. Detailed donor characteristics are summarised in Tables 1 and 2. This study was approved by the Swedish Ethical Review Authority and conducted according to the Declaration of Helsinki. All patients or next of kin and control donors provided oral and/or written informed consent in line with the ethical approval.

Peripheral blood mononuclear cells (PBMCs) from control donors and COVID-19 patients were isolated from heparinised anti-coagulated blood in SepMate tubes (Stemcell Technologies, Vancouver) using gradient density centrifugation, according to manufacturer's instructions. Briefly, 15 mL of Lymphoprep ™ (Stemcell Technologies) was pipetted below the SepMate insert and 20 mL of diluted whole blood was dispensed on top. Tubes were centrifuged at 1200 g for 10 min. The supernatant including PBMCs was carefully decanted into a new tube, followed by two washes with PBS containing 10% FCS. Platelets were removed by centrifuging the samples at 400 g for 10 min. Pellets were resuspended, cells counted and subsequently stained for flow cytometry.

Serum was collected from COVID-19 patients and control donors in BD Vacutainer serum tubes with spray-coated silica (BD Biosciences, San Jose). After coagulation for up to 2 h at room temperature (RT), serum was isolated by centrifugation at 2000 g for 10 min and immediately stored at −80°C for later analysis.

Freshly isolated PBMCs were stained with dead cell marker (Invitrogen, Carlsbad) and fluorochrome-conjugated antibodies directed against intracellular and surface markers (Supplementary table 1) for 20 min at RT in the dark. Cells were washed two times with 150 µL of PBS with 10% FCS. Next, pellets were resuspended in 100 µL of BD FACS Lysing Solution (BD Biosciences) and incubated for 10 min at RT, for cell fixation. After washing with PBS with 10% FCS, cells were permeabilised using 100 µL of BD Perm2 Permeabilizing Solution (BD Biosciences) for 10 min at RT. Subsequently, antibodies were added for intracellular staining and incubated for 30 min at RT in the dark. Cells were then washed with 150 µL of PBS with 10% FCS and incubated in a 1% formaldehyde solution for 2 h, washed and resuspended in PBS containing 10% FCS.

Samples were acquired on a BD LSR Fortessa ™ . Flow cytometric analysis was performed using FlowJo version 10.6.2 (TreeStar, Ashland).

To ensure unbiased manual gating, a blinded analysis was implemented, whereby all FCS3.0 files were renamed and coded by one person and blindly analysed by another person. All samples were compensated electronically, and gatings were based on fluorescent-minus-one (FMO) or negative controls. After all gatings were performed, samples were decoded and statistical analysis between groups and unsupervised analysis was performed. For unsupervised analysis, the following FlowJo plugins were used: DownSample (v. (Supplementary figure 2b) . The new generated FCS files were labelled according to control or patient group (moderate or severe COVID-19) and concatenated per group. Subsequently, all groups were taken to the same number of events, by downsampling to the number of events present in the group with the least number of events. The three new FCS files corresponding to control, moderate and severe COVID-19 patients were then concatenated for dimensionality reduction analysis using UMAP. UMAP was run including the markers CRTH2, CD161, CD117, CD69, HLA-DR, Ki-67, CD45RA, CD62L, CCR4, CCR6, CXCR3, CD56, NKp44 and using the following parameters: metric = euclidean, nearest neighbours = 15, and minimum distance = 0.5. Clusters of phenotypically related cells were identified using Phenograph plugin and including the same markers as for UMAP and parameters k = 30 and Run ID = auto. Finally, ClusterExplorer plugin was used to study the phenotype of the different clusters and to generate heatmaps of marker expression from those clusters.

Absolute numbers of ILCs in peripheral blood were obtained using BD Multitest ™ 6-color TBNK reagents with bead-containing BD Trucount ™ tubes (BD Biosciences), according to manufacturer's instructions. Briefly, 50 µL of anti-coagulated whole blood was added into Trucount tubes within 3 h after blood extraction. Then, an antibody mix was added for staining. After 15 min of incubation at RT in the dark, stained whole blood was fixed and red blood cells lysed with 1 × BD FACS Lysing Solution (BD Biosciences) for 2 h at RT. Samples were then fixed with 1% PFA for 2 h prior to acquisition in a FACSymphony A5 (BD Biosciences) flow cytometer. Absolute ILC cell counts were calculated using the formula: ILC number per mL ð Þ ¼ # lymphocytes events acquired * total #beads in tube * 1000 ð Þ #beads acquired * volume of whole blood stained μL ð Þ ð Þ * % ILC out of lymphocytes ILC1, ILC2 and ILCp absolute counts were calculated using their frequencies relative to total ILCs.

Heat-inactivated (56°C for 30 min) serum from all patients and controls was analysed for soluble protein biomarkers using proximity extension assay (PEA) technology (Olink AB, Uppsala, Sweden). The samples were analysed using the inflammation (v.3022) panel, including a total of 92 analytes. Data are expressed as normalised protein expression (NPX) values. NPX is an arbitrary unit on a log 2 scale to normalise data to minimise both intra-assay and inter-assay variation.

Additionally, several soluble analytes were also measured in serum or plasma by use of custom made multiplex Magnetic Luminex Screening assays (R&D Systems, Minneapolis), according to the manufacturer's instructions. Serum and plasma were diluted 1:2 prior to multiplex analysis.

Analytes from Olink data and Magnetic Luminex Screening assays that had more than 33% and 25% of missing values, respectively, were excluded from analysis. Left-censored data from the multiplex analysis were imputed using GSimp package 53 in R (v. 3.6.0) 54 .

Serum samples from all patients and controls were analysed for presence of SARS-CoV-2 antibodies, as recently described. 55 Micro-neutralisation assay for measurement of neutralising antibody titres was performed as previously described. 56 Briefly, heat-inactivated serum (56°C for 30 min) was diluted twofold starting at 1:10, mixed with an equal volume of 200 TCID50 SARS-CoV-2 (50 µL diluted serum plus 50 µL virus) and incubated for 1 h at 37°C and 5% CO 2 . Mixtures were then added to Vero E6 cells and incubated at 37°C 5% CO 2 for four days. Cells were inspected for signs of cytopathic effect (CPE) by optical microscopy. Results were expressed as the arithmetic mean of the reciprocals of the highest neutralising dilutions from the two duplicates for each sample.

Statistical analyses were performed using Prism version 8.4.3 (GraphPad Software Inc., San Diego). For comparisons between three unpaired groups, the Kruskal-Wallis test followed by Dunn's multiple comparisons test was used. Correlation analyses were performed using Spearman's rank correlation. Spearman's correlation matrix was generated with R (v.4.0.2) using package corrplot (v.0.84). Statistical differences between the moderate and severe COVID-19 patients or control donors and COVID-19 patients were determined by the two-sided Mann-Whitney U-test. Pvalues < 0.05 were considered statistically significant.

Principal component analysis (PCA) was performed in R (v.4.0.2; R Core Team, 2020) using packages Factoextra (v.1.0.7), 57 FactoMineR (v.2.3), 58 RColorBrewer (v.1.1-2) 59 and ggplot2 (v.3.3.2). 60 Data were normalised in R using the scale argument within the PCA function. Where data were missing, the values were imputed using package WaverR (v1.0) 61 

Marina García: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Writing-original draft. Efthymia Kokkinou: Conceptualization; Data curation

Writing-review & editing. Tiphaine Parrot: Conceptualization; Methodology; Writing-review & editing

Writing-review & editing. Kimia T Maleki: Conceptualization; Methodology; Writing-review & editing. Wanda Christ: Conceptualization; Methodology; Writingreview & editing

Writing-review & editing. Iva Filipovic: Conceptualization; Writing-review & editing. Hans-Gustaf Ljunggren: Conceptualization; Funding acquisition; Writingreview & editing

Writing-review & editing

Writing-review & editing. Olav Rooyackers: Conceptualization; Methodology; Writing-review & editing

Conceptualization; Writing-review & editing

Anders Sönnerborg: Conceptualization; Writing-review & editing. Soo Aleman: Conceptualization; Methodology

Writing-review & editing. Kristoffer Strålin: Conceptualization; Investigation; Methodology; Writingreview & editing

Writing-review & editing. Jonas Klingström: Conceptualization; Funding acquisition; Investigation

Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

The COVID-19 vaccine development landscape

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Clinical and immunological features of severe and moderate coronavirus disease 2019

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19

COVID-19 cytokine storm: the anger of inflammation

COVID-19: consider cytokine storm syndromes and immunosuppression

Innate lymphoid cells: 10 years on

Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues

A T-bet gradient controls the fate and function of CCR6-RORγt + innate lymphoid cells

Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit + Sca-1 + lymphoid cells

Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity

Systemically dispersed innate IL-13-expressing cells in type 2 immunity

Microbial flora drives interleukin 22 production in intestinal NKp46 + cells that provide innate mucosal immune defense

Distinct alterations in the composition of mucosal innate lymphoid cells in newly diagnosed and established Crohn's disease and ulcerative colitis

Systemic human ILC precursors provide a substrate for tissue ILC differentiation

The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells

CD4 + group 1 innate lymphoid cells (ILC) form a functionally distinct ILC subset that is increased in systemic sclerosis

Human innate lymphoid cell subsets possess tissue-type based heterogeneity in phenotype and frequency

Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus

T cells and ILC2s are major effector cells in influenza-induced exacerbation of allergic airway inflammation in mice

Innate lymphoid cells are depleted irreversibly during acute HIV-infection in the absence of viral suppression

Spatial and temporal mapping of human innate lymphoid cells reveals elements of tissue specificity

Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19

Viral and host factors related to the clinic outcome of the SARS-CoV-2 infection

Serum markers associated with severity and outcome of hantavirus pulmonary syndrome

The PD-1/PD-L1 axis and virus infections: a delicate balance

Role of the inflammasome-related cytokines Il-1 and Il-18 during infection with murine coronavirus

Interleukin 18 coexpression during respiratory syncytial virus infection results in enhanced disease mediated by natural killer cells

Interleukin-18 and IL-18 binding protein

Mild versus severe COVID-19: laboratory markers

Neutrophils restrain allergic airway inflammation by limiting ILC2 function and monocyte-dendritic cell antigen presentation

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Comprehensive mapping of immune perturbations associated with severe COVID-19

Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China

Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia

Hepatitis C virus infection induces the expression of amphiregulin, a factor related to the activation of cellular survival pathways and required for efficient viral assembly

Amphiregulin activates regulatory T lymphocytes and suppresses CD8 + T cellmediated anti-tumor response in hepatocellular carcinoma cells

Natural killer cell immunotypes related to COVID-19 disease severity

Human tissue-resident memory T cells are defined by core transcriptional and functional signatures in lymphoid and mucosal sites

Developmental plasticity allows outside-in immune responses by resident memory T cells

ILC1 confer early host protection at initial sites of viral infection

Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis

SARS-CoV-2 productively infects human gut enterocytes

In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19

Evidence for Gastrointestinal Infection of SARS-CoV-2

Activation of group 2 innate lymphoid cells after allergen challenge in asthmatic patients

ILC2 lunghoming in cystic fibrosis patients: functional involvement of CCR6 and impact on respiratory failure

Remdesivir for the treatment of Covid-19 -preliminary report

Coronavirus disease

GSimp: a Gibbs sampler based left-censored missing value imputation approach for metabolomics studies

R: a language and environment for statistical computing. R Foundation for Statistical Computing

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

Expansion of SARS-CoV-2-specific antibody-secreting cells and generation of neutralizing antibodies in hospitalized COVID-19 patients

factoextra: extract and visualize the results of multivariate data analyses

FactoMineR: an R package for multivariate analysis

ColorBrewer palettes. R package version 1.1-2

ggplot2: elegant graphics for data analysis

WaverR: data estimation using weighted averages of multiple regressions

We express our sincere gratitude to all the patients and their families as well as the clinical personnel that helped to carry out the study as part of the Karolinska KI/K COVID-19 Immune Atlas. We also thank the team at the SciLifeLab Plasma Profiling Facility in Stockholm for generating the Olink data. This study was supported by the Knut and Alice Wallenberg Foundation, Nordstjernan AB, Swedish Research Council Vetenskapsrådet (VR), Karolinska Institutet and the SciLifeLab COVID-19 National Program.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. HGL is a member of the board of XNK Therapeutics AB and Vycellix Inc.

M Garcí a et al.